Mural Oncology PLC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Mural Oncology plc reports Q3 2025 results amidst a pending acquisition by XOMA Royalty Corporation, following the discontinuation of all clinical and preclinical development programs.
Mural Oncology plc has discontinued all clinical and preclinical development, initiated a strategic review, and faces substantial doubt about its ability to continue as a going concern.
10-Q: Mural Oncology Halts Nemvaleukin Development, Explores Strategic Alternatives After Phase 3 Failure
Mural Oncology discontinues clinical development of nemvaleukin and initiates exploration of strategic alternatives following disappointing Phase 3 trial results.
Mural Oncology's Q3 2024 report details ongoing clinical trials, financial results, and operational updates following its separation from Alkermes plc.
10-Q: Mural Oncology Reports Second Quarter 2024 Financial Results and Provides Clinical Program Update
Mural Oncology's second quarter 2024 results show a net loss of $31.6 million, with ongoing clinical trials for their lead product candidate, nemvaleukin.
Mural Oncology's first quarter 2024 results show a net loss of $30.9 million, with ongoing clinical trials and a focus on advancing their immunotherapy pipeline.